Press release
Novo Nordisk A/S (NYSE: NVO) Investor Alert: Deadline in Lawsuit on September 30, 2025
A Deadline is coming up on September 30, 2025 in the lawsuit for certain investors in Novo Nordisk A/S (NYSE: NVO).
Investors who purchased shares of Novo Nordisk A/S (NYSE: NVO) have certain options and there are strict and short deadlines running. Deadline: September 30, 2025. Novo Nordisk A/S (NYSE: NVO) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
According to the complaint filed in the U.S. District Court for the District of New Jersey the plaintiff alleges on behalf of purchasers of Novo Nordisk A/S (NYSE: NVO) common shares between May 7, 2025 and July 28, 2025, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between May 7, 2025 and July 28, 2025, the defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Novo Nordisk's growth potential, that notably, Novo Nordisk's asserted potential to capitalize on the compounded market greatly understated the potential impact of the personalization exception to the compounded GLP-1 exclusion and overstated the likelihood that such patients would switch to Novo Nordisk's branded alternatives, and that the defendants greatly overstated the potential GLP-1 market or otherwise, Novo's capability to penetrate said markets to achieve continued growth.
Those who purchased shares of Novo Nordisk A/S (NYSE: NVO) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Novo Nordisk A/S (NYSE: NVO) Investor Alert: Deadline in Lawsuit on September 30, 2025 here
News-ID: 4190592 • Views: …
More Releases from Shareholders Foundation, Inc.
Lawsuit filed for Investors who lost money with shares of Primo Brands Corporati …
An investor, who purchased shares of Primo Brands Corporation (NYSE: PRMB), filed a lawsuit over alleged violations of Federal Securities Laws in connection with certain allegedly false and misleading statements.
Investors who purchased a significant amount of shares of Primo Water (formerly NYSE: PRMW) between June 17, 2024 through November 8, 2024, and/or purchased a significant amount of shares Primo Brands Corporation (NYSE: PRMB) between November 11, 2024 through November 6,…
Lawsuit Alert: Investors who lost a substantial amount with Telix Pharmaceutical …
An investor, who purchased shares of Telix Pharmaceuticals Limited (NASDAQ: TLX), filed a lawsuit in the U.S. over alleged violations of Federal Securities Laws by Telix Pharmaceuticals Limited in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Telix Pharmaceuticals Limited (NASDAQ: TLX) have certain options and for certain investors are short and strict deadlines running. Deadline: January 9, 2026. NASDAQ: TLX investors should contact the Shareholders…
Investigation announced for Long-Term Investors in shares of Savara Inc. (NASDAQ …
An investigation was announced for long-term investors in shares of Savara Inc. (NASDAQ: SVRA) concerning potential breaches of fiduciary duties by certain directors of Savara Inc.
Investors who are current long term investors in Savara Inc. (NASDAQ: SVRA) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: SVRA stocks…
Lawsuit filed for Investors who lost money with shares of Inspire Medical System …
An investor, who purchased shares of Inspire Medical Systems, Inc. (NYSE: INSP), filed a lawsuit over alleged violations of Federal Securities Laws by Inspire Medical Systems, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Inspire Medical Systems, Inc. (NYSE: INSP) have certain options and for certain investors are short and strict deadlines running. Deadline: January 5, 2026. NYSE: INSP investors should contact the Shareholders…
More Releases for Novo
Incretin Market | Key Players-Profil, Takeda, Novo Nordisk, GlaxoSmithKline
Incretin Market size was valued at USD 20.5 Billion in 2024 and is projected to reach USD 38.2 Billion by 2033, exhibiting a CAGR of 7.2% from 2026 to 2033.
What are the potential factors contributing to the growth of the Incretin market?
The Incretin market is experiencing growth primarily due to the increasing prevalence of diabetes and obesity worldwide, which drives the demand for effective glucose-lowering therapies. Advances in medical research…
Novo Nordisk's "Employee Diet" Trims Workforce By 9,000
Novo Nordisk (NYSE: NVO) just put 9,000 employees on the chopping block [https://finance.yahoo.com/news/novo-just-fired-9-000-172419344.html] in what it's calling an effort to "reduce complexity." Translation: the world's onetime obesity drug darling is cleaning house after years of chasing growth that turned into bloat.
A year ago, Novo was Europe's most valuable company, sitting atop the GLP-1 boom like a king fattened on its own miracle cure. Today, it's a retrenchment story. The stock…
Semaglutide Market Future Business Opportunities 2025-2032 | Novo Nordisk
The qualitative latest Research report (2025-2032) on the Semaglutide Market by Coherent Market Insights Provides a deep dive into key market trends, drivers, challenges, and the competitive landscape. It analyzes market size, revenue, production, and CAGR using validated methodologies to ensure precision. The report highlights tech innovation, pricing trends, consumer behavior, and investment potential - empowering businesses to make informed, strategic moves.
Request a Sample Copy: https://www.coherentmarketinsights.com/insight/request-sample/3314
Focused on growth and future…
Diabetes Therapeutic Market Innovations, Competitive Analysis, New Business Deve …
The Covid-19 (coronavirus) pandemic is impacting society and the overall economy across the world. The impact of this pandemic is growing day by day as well as affecting the supply chain. The COVID-19 crisis is creating uncertainty in the stock market, massive slowing of supply chain, falling business confidence, and increasing panic among the customer segments. The overall effect of the pandemic is impacting the production process of several industries…
Hormonal Replacement Therapeutics - Pipeline Analysis 2018 | Novo Nordisk
Hormonal replacement therapy is a type of treatment wherein patients receive a course of hormones in order to get relieve from the menopause related problems. The therapy involves administration of synthetic estrogen and progesterone to overcome decreasing hormone level of women.
Download the sample report @ https://www.pharmaproff.com/request-sample/1136
The most common signs and symptoms observed in patients with decreased hormone level are irregular menstrual cycles, and psychological symptoms (mood swings, anxiety, and…
Antidiabetics Market Size, Historical Growth Analysis By top Key Player - Boehri …
Market Study Report: The Report entitled 2018-2024 Global Antidiabetics Market Report explores the essential factors of the Antidiabetics market considering such as industry situations, market demands, market players adopted business strategies and their growth scenario. The Global Antidiabetics market has been separated by this report based on the key players profiles, Type, Application and Regions.
Germany antidiabetics industry accounted for largest revenue size of USD 4,461.7 million of Europe antidiabetics industry…
